Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbCellera Biologics Inc.ABCL · Entity 4118 | Director · Chief Technology Officer | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbCellera Biologics Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2036-01-01 | Direct | 5,201,069 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 539,265 · Balance 5,201,069 F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 17:08 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 539,265 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001834418-26-000002 · wk-form4_1767632934.xml · derivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,201,069 Underlying: Common Shares · 539,265 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 20:40 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 832,033 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001628280-25-000235 · wk-form4_1735936840.xml · derivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661,804 Underlying: Common Shares · 832,033 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 22:38 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare option (right to buy) · Derivative | 83,334 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001628280-24-029675 · wk-form4_1719268705.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,829,771 Underlying: Common Shares · 83,334 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 22:38 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 83,334 | $0.19 | $15,666.79 |
DisclosureSEC source: 0001628280-24-029675 · wk-form4_1719268705.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,123,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2024 Filed Jan 16, 2024 23:23 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 770,416 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001703057-24-000008 · wk-form4_1705447421.xml · derivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,913,105 Underlying: Common Shares · 770,416 shares Expires 2034-01-14 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:38 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 20,000 | $5.19 | $103,800.00 |
DisclosureSEC source: 0001703057-23-000030 · wk-form4_1694723915.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,040,122 Read SEC document |
| May 05, 2023 Filed May 9, 2023 19:02 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-23-028214 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,142,689 Underlying: Common Shares · 250,000 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 19:02 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 250,000 | $0.19 | $47,500.00 |
DisclosureSEC source: 0001209191-23-028214 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,020,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 17:28 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Options (right to buy) · Derivative | 462,535 | $0.00 Strike: $13.18 | $0.00 |
DisclosureSEC source: 0001209191-22-059573 · doc4.xml · derivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392,689 Underlying: Common Shares · 462,535 shares Expires 2032-12-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 16, 2022 Filed May 17, 2022 19:07 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 200,000 | $6.34 | $1,267,780.00 |
DisclosureSEC source: 0001209191-22-029542 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,770,122 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $6.22 to $6.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 00:49 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 230,789 | $8.66 | $1,998,632.74 |
DisclosureSEC source: 0001209191-22-014395 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570,122 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased at prices ranging from $8.48 to $8.80. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:49 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-068844 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,524,134 Underlying: Common Shares · 250,000 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:49 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 250,000 | $0.19 | $47,500.00 |
DisclosureSEC source: 0001209191-21-068844 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,589,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Feb 4, 2022 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GiftCommon Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 2 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 F2 · shares: This transaction represents a charitable donation of 250,000 common shares the reporting person donated on December 8, 2021. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:01 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Option · Derivative | 406,020 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068851 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,930,154 Underlying: Common Shares · 406,020 shares Expires 2031-12-07 F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 19:16 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-067491 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774,134 Underlying: Common Shares · 83,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 19:16 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 83,333 | $14.96 | $1,246,661.68 |
DisclosureSEC source: 0001209191-21-067491 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-067941 · doc4a.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774,134 Underlying: Common Shares · 83,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 83,333 | $0.19 | $15,833.27 |
DisclosureSEC source: 0001209191-21-067941 · doc4a.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The original price was listed as $14.96 which is an administrative error. The correct price is $0.19. Read SEC document |
| November 30, 2021 Filed Feb 4, 2022 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GiftCommon Shares | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 F1 · shares: This transaction represents a charitable donation of 83,333 common shares the reporting person donated on November 30, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 333,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0000899243-21-024295 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,667 Underlying: Common Shares · 333,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on November 8, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. F5 · derivative.expiration_date: Expiration date corrected from the date listed on the Form 3 filed on December 11, 2020. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 333,333 | $0.19 | $63,333.27 |
DisclosureSEC source: 0000899243-21-024295 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:01 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022990 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 273,630 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F2 · kind: The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 23,000 shares, with the purchase by the Reporting Person of 6,000 shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 17,000 shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F3 · ownership.nature: These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 17,000 | $20.00 | $340,000.00 |
DisclosureSEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 2 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 61,580 Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 6,000 | $20.00 | $120,000.00 |
DisclosureSEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,000 Read SEC document |
| December 10, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantStock Option (right to buy) · Derivative | 190,800 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034342 · doc4.xml · derivative · entry 6 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,800 Underlying: Common Shares · 190,800 shares Expires 2030-12-10 F7 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 29, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0000899243-20-034342 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Shares · 2,000,000 shares Expires 2030-10-29 F3 · derivative.exercise_price: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F4 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00. F7 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein. F5 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F3 · derivative.underlying_shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F3 · balance_after: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.